Clinical Trials Browser

Interventional × zipalertinib × 30 days × Clear all

NCT05967689 2026-03-10

REZILIENT2

Phase 2 Recruiting

Carcinoma, Lung Diseases

NCT05973773 2026-03-10

REZILIENT3

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases